Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients from the DBCG HYPO Randomized Trial - Takeaways - MDSpire

Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients from the DBCG HYPO Randomized Trial

  • By

  • Demet Özcan

  • Patricia Switten Nielsen

  • Jan Alsner

  • Mette Holck Nielsen

  • Else Maae

  • Marie Louise Holm Milo

  • Jens Overgaard

  • Birgitte Vrou Offersen

  • Trine Tramm

  • March 13, 2026

  • 0 min

Share

  • 1

    Radiotherapy significantly reduces local recurrence risk and improves long-term survival in breast cancer patients.

  • 2

    Hypofractionated radiotherapy regimens may enhance immune responses more effectively than conventional schedules.

  • 3

    Tumor-infiltrating lymphocytes (TILs) are a promising prognostic biomarker, particularly in aggressive breast cancer subtypes.

  • 4

    The study investigates the prognostic and predictive value of TILs in node-negative breast cancer patients receiving radiotherapy.

  • 5

    Findings may reveal how immune infiltration impacts outcomes and treatment benefits based on estrogen receptor status.

Original Source(s)

Correlation of Tumor Immune Response with Prognosis in Node-Negative Breast Cancer Patients from the DBCG HYPO Randomized Trial

  • by Demet Özcan, Patricia Switten Nielsen, Jan Alsner, Mette Holck Nielsen, Else Maae, Marie Louise Holm Milo, Jens Overgaard, Birgitte Vrou Offersen, Trine Tramm

  • March 13, 2026

Related Content

Errors in Abstract and Table 1

  • May 15, 2026

Breast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45 to 64 Years

HiGATE: hierarchical graph attention for multi-scale tissue encoder in computational pathology